Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : Stock Swap -- Ignore unavailable to you. Want to Upgrade?

To: Evan Dimmer who wrote (13669)	5/6/1998 2:53:00 PM
From: Jeffrey S. Mitchell	Read Replies (1) \| Respond to of 17305

Re: Did anyone hear that in "worst case scenarios" they are going to have it ready for humans in possibly less than 4 months? I think you mean "best case" scenario... or should I say "pipe dream" scenario. Even if this may prove to be the most promising treatment for cancer ever, we're still talking mice. Even if this were humans, they'd still have to figure out how to manufacture it, i.e. how to even produce it in commercial quantities. So, if you're looking to buy and hold short-term hoping for a saleable product out of all this, forget it. That's not to say you can't make money going long, just not for the reason you cited. - Jeff

To: Evan Dimmer who wrote (13669)	5/6/1998 2:59:00 PM
From: Trader X	Read Replies (3) \| Respond to of 17305

Exactly right. Volatility aside, this could be a good keeper long term. If it does get back to 20-ish, I may be tempted to stock up on it for the long haul, because even if you don't project earnings for another 2-3 years, the earnings could be devastatingly rich when they come. But there will be hard pressure to get this into humans quickly. News of a faster timetable will only serve to place a higher floor under the price. The UK is beginning tests on humans on a competitive drug in 6 months, and this should speed things up for ENMD: <<LONDON, May 6 (Reuters) -British doctors said on Wednesday they expect to begin human trials of a new cancer drug that cuts off blood supply to tumours ahead of U.S. counterparts who are working on a similar approach. Dr David Secher, director of drug development for the Cancer Research Campaign, said the charity hopes to test Combretastatin A4 on humans in November. ''Our animal studies have been sufficiently encouraging for us to go into clinical studies. I think it is a very interesting area,'' Secher told Reuters. Unlike conventional treatments that target the cancer cells themselves, Combretastatin works by selectively damaging blood vessels that supply the cells with the oxygen and nutrients they need to survive and grow. It ''starves'' the cancer in a similar way to angiostatin and endostatin, two drugs which attracted worldwide interest this week after tests in the United States showed they completely wiped out tumours in mice. Combretastatin is a mad-made derivative of the extract of the African Bush Willow. It was discovered by Professor Bob Pettit, of Arizona State University, which has licensed it to Oxigene (OXGN - news; OXGN.ST), a Swedish medical technology company. News of the U.S. trials of angiostatin and endostatin has sent shares soaring in EntreMed Inc (ENMD - news), which has rights to those drugs, despite warnings that they might not produce the same results in humans. EntreMed said it would be at least a year before the drug combination could be tested on humans.>>